1. Basic Product Identification
INN Name: Agomelatine
Therapeutic Class: Antidepressant
Pharmacological Class: Melatonergic antidepressant
ATC Code: N06AX22
Primary Indication: Major Depressive Disorder (MDD)
Route of Administration: Oral
Dosage Form: Tablet (usually film-coated)
2. Therapeutic Knowledge
Used for Major Depressive Disorder in adults
Improves:
Mood
Sleep cycle
Anxiety symptoms associated with depression
Unique advantage:
No sexual dysfunction (unlike SSRIs)
No withdrawal syndrome
Not first-line in all countries due to liver safety monitoring requirement
3. Mechanism of Action (MOA)
Agomelatine works through a dual mechanism:
Melatonin receptor agonist
MT1 receptor → improves sleep initiation
MT2 receptor → improves circadian rhythm resynchronization
Serotonin receptor antagonist
Blocks 5-HT2C receptors
Increases dopamine and norepinephrine release in frontal cortex
???? Result:
Circadian rhythm normalization
Antidepressant effect via dopamine/norepinephrine increase
4. Pharmacokinetics (ADME)
Absorption: Rapid but low bioavailability (~5%)
Tmax: ~1–2 hours
Protein binding: ~95%
Metabolism: Extensive hepatic (CYP1A2 mainly, also CYP2C9)
Half-life: ~1–2 hours (short, but effect is functional not plasma-based)
Excretion: Mainly urine as metabolites
⚠️ CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) are contraindicated.
5. Dosage & Administration
Starting dose: 25 mg once daily at bedtime
Dose increase: 50 mg once daily if insufficient response after 2 weeks
Administration: Bedtime (important for circadian action)
Liver monitoring:
Baseline LFT mandatory
Regular monitoring during treatment
6. Formulation Knowledge
Immediate release film-coated tablets
Typical strengths:
25 mg
50 mg
Excipients:
Lactose monohydrate
Povidone
Crospovidone
Magnesium stearate
Film coating polymers (HPMC, PEG, titanium dioxide)
7. Raw Materials Knowledge
API: Agomelatine (synthetic melatonergic compound)
Key raw intermediates:
Naphthalene derivatives
Acetamide intermediates
Critical impurity controls:
N-desmethyl agomelatine
Oxidative degradation products
8. Manufacturing Process Knowledge
Typical API synthesis involves:
Multi-step organic synthesis
Formation of naphthalene core structure
Amide coupling reactions
Purification via recrystallization / chromatography
Tablet manufacturing:
Direct compression or wet granulation
Low-dose API → high content uniformity control critical
Sensitive to moisture and light
9. Analytical & QC Knowledge
Key tests:
Assay (HPLC)
Related substances / impurities
Dissolution testing (USP/Ph.Eur)
Content uniformity (critical due to low dose)
Stability-indicating methods
Residual solvents (GC)
Stability indicating methods must detect:
Oxidation products
Photodegradation products
10. Regulatory Knowledge
Approved in EU (EMA), India, several other countries
Not FDA-approved (US)
Requires Risk Management Plan (RMP) in EU
Mandatory:
Liver function monitoring warnings
Controlled distribution in some regions due to hepatotoxicity risk
11. Storage & Stability
Store below 25°C
Protect from:
Moisture
Light
Shelf life: typically 2–3 years
Stability concerns:
Oxidation
Photodegradation
12. Packaging Knowledge
Alu-Alu blister preferred (moisture protection)
Strip packaging also used
Secondary packaging includes:
Liver monitoring warning leaflet
Patient information leaflet
13. Safety & Toxicology
Key risks:
Hepatotoxicity (major concern)
Elevated liver enzymes
Rare severe liver injury
Contraindications:
Liver impairment
CYP1A2 inhibitors (strong)
Side effects:
Headache
Dizziness
Fatigue
GI disturbances
14. Market & Commercial Knowledge
Positioning:
“Circadian rhythm correcting antidepressant”
Competitors:
SSRIs (sertraline, escitalopram)
SNRIs (venlafaxine, duloxetine)
Market advantage:
Sleep improvement without benzodiazepines
Market limitation:
Liver monitoring reduces adoption
15. Intellectual Property (IP)
Original developer: Servier (France)
Patent status: Mostly expired in many regions
Generics available in multiple markets
Still protected via:
Formulation patents (in some countries)
Process patents (limited)
16. Environmental & EHS Knowledge
Pharmaceutical waste must be treated as hazardous
Avoid API release into wastewater
Solvent recovery systems recommended
Worker safety:
PPE agomelatine API Manufacturer in Huambo required during API handling
Dust control essential
17. Export Documentation Knowledge
Typical requirements:
COA (Certificate of Analysis)
GMP Certificate
DMF (Drug Master File) / ASMF
Stability data package
MSDS (Material Safety Data Sheet)
Shipping validation documents
18. Business Development Knowledge
Target buyers:
Generic pharmaceutical companies
CNS-focused formulators
Key selling points:
Differentiated antidepressant mechanism
Patent-expired API opportunities
Risks:
Regulatory hesitation due to hepatotoxicity
Strategy:
Position as “premium niche antidepressant API”
19. Advanced Technical Knowledge
Circadian rhythm pharmacology is central
Not a monoamine reuptake inhibitor (unlike SSRIs)
Unique chronobiological drug class
Requires chronotherapy-based dosing concept
20. AI & Digital Knowledge (Modern Pharma)
Applications:
Predict liver toxicity using AI models
Stability prediction via ML degradation models
Supply chain forecasting for CNS drugs
Digital pharmacovigilance tracking of liver injury reports
21. Sales Team Product Knowledge Checklist
Sales team must know:
Indication (MDD only)
Dose timing (bedtime critical)
Liver monitoring requirement
CYP1A2 interactions
Key differentiator: sleep normalization
Not habit-forming
Market limitations (hepatotoxicity monitoring)
22. Most Important Technical Documents
DMF / ASMF
COA (API + finished product)
Stability reports (ICH)
Bioequivalence studies
Safety pharmacology reports
Impurity profile report
Regulatory approval dossier (EU SmPC)
23. Ultimate Pharma Product Mastery Summary
Agomelatine is:
A dual melatonin agonist + serotonin antagonist antidepressant
Highly unique in circadian rhythm correction
Limited by liver safety monitoring
Strong niche product in CNS segment
Ideal for differentiation vs SSRIs/SNRIs